Biomedical subjects

Norio Mitsuhashi

Publications and source records attributed to Norio Mitsuhashi.

39 records · Page 3Linked to original sources

PubMedDate not supplied

Radiotherapy for localized hormone-refractory prostate cancer in Japan.

BACKGROUND: The role of radiotherapy for patients with localized hormone-refractory cancer has not been well documented. MATERIALS AND METHODS: The Patterns of Care Study in Japan examined the records of 311 patients with prostate cancer treated with radiotherapy during the period 1996--1998. Of them, 61 patients (19.6%) with regionally localized hormone-refractory cancer were selected. Local progression or biochemical failure was observed after a median duration of 15.9 months of androgen deprivation. At the time of radiotherapy, 49 patients (80.4%) had T3-4 tumors and 15 (26.8%) had regional lymph node metastases. External beam radiotherapy was performed with a median total dose of 60 Gy. RESULTS: Although distant metastases or regional lymph node metastases were seen in 22 patients (36.1), local progression was observed in one patient (1.6%). The five-year overall and progression-free survival rates were 51.6% and 43.5%, respectively. CONCLUSION: Radiotherapy had an excellent local control rate for hormone-refractory cancer.

Aged↗

PubMedDate not supplied

Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group.

BACKGROUND: Superficial esophageal cancer (SEC) is defined as esophageal cancer limited to the submucosal layers, including mucosal cancer and submucosal cancer, and is squamous cell carcinoma in most patients. In 2000, the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group for SEC published a consensus guideline of standard radiotherapy methods. In this study, the interim treatment outcomes of SEC patients, who had received radiation therapy following the standard radiotherapy methods, were investigated. PATIENTS AND METHODS: From 2000 to 2003, a total of 141 SEC patients were treated in 24 institutions in Japan. RESULTS: The 1-, 2- and 3-year survival rates were 95%, 90% and 90%, respectively, for patients with mucosal cancer and 90%, 81% and 70%, respectively, for patients with submucosal cancer. The overall survival was better in patients who had undergone chemotherapy than in patients who had received radiation therapy alone, though the difference was not statistically significant. The clinical target volume (CTV) did not influence overall survival and intracavitary irradiation did not influence the local control rate in either patients with mucosal or submucosal cancer. Radiation-induced esophageal ulcer was not observed in this series. CONCLUSION: The standard radiotherapy methods are safe and effective for treating SEC. However, the usefulness of chemotherapy and intracavitary irradiation and the optimal setting of the CTV should be clarified by future randomized trials.

Aged↗

PubMedDate not supplied

Chemoradiotherapy with and without esophagectomy for advanced esophageal cancer.

BACKGROUND/AIMS: To evaluate the impact of surgery on survival after chemoradiotherapy, we analyzed the long-term outcome of patients with advanced esophageal cancer. METHODOLOGY: Data on 92 consecutive patients with T3 or T4 esophageal cancer who were initially treated by chemoradiotherapy were reviewed retrospectively. Of 82 patients who completed the planned schedule, 35 patients underwent esophagectomy (CRT+E Group) and 47 patients received definitive chemoradiotherapy (CRT Group). RESULTS: A response to chemoradiotherapy was obtained in 71% of all 92 patients. The 1- and 3-year survival rates in the patients with T3M0 were 87 and 44 percent respectively, while these in the patients with T4 and/or M1(Lymph) disease were 47 and 20 percent. Although there was no difference in overall survival between the CRT+E Group and the CRT Group, the survival of responders in the CRT+E Group was significantly higher than that of those in the CRT Group (P=0.0448). The locoregional recurrence rate of responders in the CRT Group was higher than that in the CRT+E Group. Multivariate analysis showed that the independent prognostic factors were response, M(Lymph), and esophagectomy. CONCLUSIONS: Although this study was retrospective and nonrandomized, esophagectomy after chemoradiotherapy might improve the survival of responders for locoregional control.

Aged↗